Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Catalent Joins Global Initiative to Develop Malaria Vaccine

By Catalent Pharma Solutions | December 15, 2016

Catalent Biologics collaborates with PATH Malaria Vaccine Initiative to create antibodies for malaria vaccine research and development.

Catalent Pharma Solutions, global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an agreement with PATH, an international nonprofit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).

Under the agreement, Catalent Biologics will employ its proprietary GPEx cell line technology, coupled with a state-of-the-art ambr workstation, which mimics the characteristics of classical bioreactors at micro scale, to develop, optimize the process for expression, and manufacture antibodies under cGMP conditions at its Madison, WI facility, for further investigation by MVI and its partners.

“Catalent has significant experience partnering with companies for the successful development of antibodies for innovative applications,” commented Mike Riley, vice president and general manager of Catalent Biologics. “PATH is a leader in the field, working with partners to pioneer vaccine development approaches that could ultimately contribute to malaria elimination efforts. We are excited to be able to apply our technology and expertise to advance this important program.”

PATH’s MVI is working to accelerate the development of malaria vaccines and to ensure access where they are needed most across the globe. Through partnerships, PATH helps drive the development of better malaria vaccines. MVI maintains a portfolio of candidates, both preclinical and early clinical, and at least one advanced clinical project.

Catalent’s proprietary GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, through to commercial scale production. To date, seven GPEx-based antibody and protein products are approved and marketed, and 34 therapeutic candidates are currently in the clinic across the world.

Catalent’s commercial biomanufacturing facility in Wisconsin was completed in June 2013. Designed for flexible cGMP production from 10 L up to 1,000 liters, and non-GMP production up to 250 liters, the site features extensive single-use technologies and unidirectional flow to maximize efficiency and safety. Catalent recently announced the commencement of work to extend its Madison facility and add 22,000 square feet of space accommodating two 2,000 liter bioreactors that will allow the company to support late-phase clinical, and commercial production of up to 4,000 liter batches.  www.catalentbiologics.com.

(Source: Catalent Pharma Solutions)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE